Cart
sales@molnova.com
GSK872 HCl（1346546-69-7 free base）
CAS No. 2703752-81-0
GSK872 HCl（1346546-69-7 free base）( —— )
Catalog No. M35224 CAS No. 2703752-81-0
GSK872 HCl（1346546-69-7 free base） (GSK2399872A) is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity (IC50: 1.8 nM) and inhibits kinase activity (IC50: 1.3 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 75 | In Stock |
|
| 5MG | 68 | In Stock |
|
| 10MG | 116 | In Stock |
|
| 25MG | 188 | In Stock |
|
| 50MG | 299 | In Stock |
|
| 100MG | 461 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK872 HCl（1346546-69-7 free base）
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK872 HCl（1346546-69-7 free base） (GSK2399872A) is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity (IC50: 1.8 nM) and inhibits kinase activity (IC50: 1.3 nM).
-
DescriptionGSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.
-
In VitroCell Viability AssayCell Line:HT-29 cells Concentration:0.01, 0.03 , 0.1, 0.3, 1, and 3 μM Incubation Time:24 hours Result:Blocked TNF-induced necroptosis in a concentration-dependent manner.
-
In VivoAnimal Model:Eight weeks old Sprague-Dawley male rats with 300-320 g body weight (rat SAH model)Dosage:25 mM/6 μL Administration:Syringe pump (intracerebroventricular) at 30 min after SAHResult:Attenuated brain edema, improved neurological function and decreased the number of necrotic cells in the ipsilateral cortex. Decreased the expression of RIPK3, MLKL and cytoplasmic HMGB1 at 72 h after SAH in the ipsilateral cortex.
-
Synonyms——
-
PathwayApoptosis
-
TargetRIP kinase
-
RecptorRIP kinase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2703752-81-0
-
Formula Weight419.94
-
Molecular FormulaC19H18ClN3O2S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 10 mg/mL (23.81 mM; Ultrasonic (<60°C); H2O : 2.5 mg/mL (5.95 mM; Ultrasonic (<60°C))
-
SMILESCl.CC(C)S(=O)(=O)c1ccc2nccc(Nc3ccc4scnc4c3)c2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mandal P, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014 Nov 20;56(4):481-95.?
molnova catalog
related products
-
CSLP43
CSLP43 (RIPK2 inhibitor CSLP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay.
-
Zharp2-1
Zharp2-1, a RIPK2 inhibitor, inhibits the transcription of inflammatory cytokines induced by MDP-induced or Listeria monocytogenes infection and alleviates MDP-induced peritonitis symptoms in mice, which can be used for the study of inflammatory bowel disease (IBD).
-
RIP1-IN-22
RIP1-IN-22 is a highly potent, orally available, and brain-penetrating RIP1 kinase inhibitor with pKi of 9.04.
